Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy: Association with regression of hepatic fibrosis

Journal of Hepatology

Volumn 30, Issue 1, 1999, Pages 1-7

  Tsushima, Hirofumi ^a   Kawata, Sumio ^a   Tamura, Shinji ^a   Ito, Nobuyuki ^a   Shirai, Yasuhiro ^a   Kiso, Shinichi ^a   Doi, Yoshinori ^a   Yamada, Akira ^a   Oshikawa, Osamu ^a   Matsuzawa, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Chronic hepatitis C; Enzyme linked immunosorbent assay; Interferon a; Liver fibrosis; Transforming growth factor 1

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGRESSION ANALYSIS;

EID: 0032955814     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80001-4     Document Type: Article

References (41)

1. Marcos R, Michael AD. Hepatic fibrosis. Gastroenterology. 76:1979;849-863.
2. Graziella B, Giorgio B. Liver fibrosis and extracellular matrix. J Hepatol. 8:1989;115-124.
3. Czaja MJ, Weiner FR, Fladers KC, Giambrone M-A, Wind R, Biempica L, et al. In vitro and in vivo association of transforming growth factor-β1 with hepatic fibrosis. J Cell Biol. 108:1989;2477-2482.
4. Armendariz-Borunda J, Seyer JM, Kang AH, Raghow R. Regulation of TGFβ gene expression in rat liver intoxicated with carbon tetrachloride. FASEB J. 4:1990;215-221.
5. Nakatsukasa H, Evarts RP, Hsia C-C, Thorgeirsson SS. Transforming growth factor β1 and Type I procollagen transcripts during regeneration and early fibrosis of rat liver. Lab Invest. 63:1990;171-180.
6. Ignotz RA, Massagué J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 261:1986;4337-4345.
7. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 83:1986;4167-4171.
8. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-β increases steady-state levels of type I procollagen and fibronectin messenger RNAs posttran-scriptionally in cultured human dermal fibroblasts. J Clin Invest. 79:1987;1285-1288.
9. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, et al. Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6:1987;1899-1904.
10. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA. 92:1995;2572-2576.
11. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease: effects of interferon alfa therapy. N Engl J Med. 324:1991;933-940.
12. Realdi G, Alberti A, Rugge M. Long-term follow up of acute and chronic non-A, non-B hepatitis; evidence of progression to liver cirrhosis. Gut. 23:1982;270-275.
13. Dienstag JL. Non-A, non-B hepatitis. 1. Recognition, epidemiology, and clinical features. Gastroenterology. 85:1983;439-462.
14. Rubinstein M. Multiple interferon subtypes: the phenomenon and its relevance. J Interferon Res. 7:1987;545-551.
15. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie AM, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 315:1986;1575-1578.
16. Thomson BJ, Doran M, Lever AML, Webster ADB. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gamma-globulin replacement therapy. Lancet. i:1987;539-541.
17. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC. Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J. 298:1989;80-82.
18. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
19. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
20. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
21. Jimenez SA, Freundlich B, Rosenbloom T. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest. 74:1984;1112-1116.
22. Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R, et al. Quantitative analysis of transforming growth factor-β1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology. 21:1995;298-304.
23. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer. 73:1994;2275-2279.
24. Trotter J, Washington K, Kong FM, Jirtle R. Plasma transforming growth factor-β levels in hepatic fibrosis [abstract]. Hepatology. 22:1995;287A.
25. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med. 60:1990;215-222.
26. Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trute A, et al. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and prediction of infectivity. Lancet. 335:1990;1419-1422.
27. McCullough AJ, Stassen WN, Wiesner RH, Czaja AJ. Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis. J Lab Clin Med. 109:1987;55-61.
28. Risteli J, Bachinger HP, Engel J, Furthmayr H, Timpl R. 7-S collagen: characterization of unusual basement membrane structure. Eur J Biochem. 108:1980;239-250.
29. Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA. 77:1980;3494-3498.
30. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
31. Frei A, Zimmermann A, Weigand K. The n-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology. 4:1984;830-834.
32. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology. 11:1990;599-605.
33. Nakatsukasa H, Nagy P, Everts RP, Hsia C-C, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factor-β1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest. 85:1990;1833-1843.
34. Bedossa P, Poynard T, Mathurin P, Lemaigre G, Chaput JC. Transforming growth factor β1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. Gut. 34:(Suppl):1993;S146-S147.
35. Numaguchi S, Okuno M, Moriwaki H, Muto Y. Modulation of collagen synthesis and degradation by retinoids and cytokines in 3T3 L1 preadipocytes. Intern Med. 33:1994;309-316.
36. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon-α and γ inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology. 21:1995;1003-1010.
37. 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology. 18:1993;1344-1349.
38. Teran JC, Mullen KD, Hoofnagle JH, McCullough AJ. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-α. Hepatology. 19:1994;849-856.
39. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Longterm decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon-α. Hepatology. 22:1995;426-431.
40. Ishibashi K, Kashiwagi T, Ito A, Tanaka Y, Nagasawa M, Toyama T, et al. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology. 24:1996;27-31.
41. Tassopoulos NC, Karvountzis G, Touloumi G, Delladetsima JK, Papatheodoridis GV, Katsoulidou A, et al. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol. 91:1996;1734-1738.